TNF-α inhibition with etanercept significantly reduced urinary protein excretion (514 vs 703 mg/day; P<0.05) and renal inflammation markers in DOCA-salt hypertensive rats without affecting blood pressure.
Does etanercept reduce renal injury and inflammation in DOCA-salt hypertensive rats?
TNF-α inhibition with etanercept reduces renal inflammation and injury in mineralocorticoid-induced hypertension independent of blood pressure lowering.
Absolute Event Rate: 514% vs 703%
p-value: p=<0.05
Studies suggest that the inflammatory cytokine TNF-α plays a role in the prognosis of end-stage renal diseases. We previously showed that TNF-α inhibition slowed the progression of hypertension and renal damage in angiotensin II salt-sensitive hypertension. Thus, we hypothesize that TNF-α contributes to renal inflammation in a model of mineralocorticoid-induced hypertension. Four groups of rats ( n = 5 or 6) were studied for 3 wk with the following treatments: 1) placebo, 2) placebo + TNF-α inhibitor etanercept (1.25 mg·kg −1 ·day −1 sc), 3) deoxycorticosterone acetate + 0.9% NaCl to drink (DOCA-salt), or 4) DOCA-salt + etanercept. Mean arterial blood pressure (MAP) measured by telemetry increased in DOCA-salt rats compared with baseline (177 ± 4 vs. 107 ± 3 mmHg; P < 0.05), and TNF-α inhibition had no effect in the elevation of MAP in these rats (177 ± 8 mmHg). Urinary protein excretion significantly increased in DOCA-salt rats compared with placebo (703 ± 76 vs. 198 ± 5 mg/day); etanercept lowered the proteinuria (514 ± 64 mg/day; P < 0.05 vs. DOCA-salt alone). Urinary albumin excretion followed a similar pattern in each group. Urinary monocyte chemoattractant protein (MCP)-1 and endothelin (ET)-1 excretion were also increased in DOCA-salt rats compared with placebo (MCP-1: 939 ± 104 vs. 43 ± 7 ng/day, ET-1: 3.30 ± 0.29 vs. 1.07 ± 0.03 fmol/day; both P < 0.05); TNF-α inhibition significantly decreased both MCP-1 and ET-1 excretion (409 ± 138 ng/day and 2.42 ± 0.22 fmol/day, respectively; both P < 0.05 vs. DOCA-salt alone). Renal cortical NF-κB activity also increased in DOCA-salt hypertensive rats, and etanercept treatment significantly reduced this effect. These data support the hypothesis that TNF-α contributes to the increase in renal inflammation in DOCA-salt rats.
Elmarakby et al. (Wed,) conducted a other in DOCA-salt hypertension. Etanercept (TNF-α inhibitor) vs. Placebo or DOCA-salt alone was evaluated on Urinary protein excretion (p=<0.05). TNF-α inhibition with etanercept significantly reduced urinary protein excretion (514 vs 703 mg/day; P<0.05) and renal inflammation markers in DOCA-salt hypertensive rats without affecting blood pressure.